Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of VYNE Therapeutics Inc (NASDAQ: VYNE) was $1.62 for the day, up 18.25% from the previous closing price of $1.37. In other words, the price has increased by $18.25 from its previous closing price. On the day, 4.96 million shares were traded. VYNE stock price reached its highest trading level at $1.7302 during the session, while it also had its lowest trading level at $1.365.
Ratios:
Our analysis of VYNE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.47 and its Current Ratio is at 4.47. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on November 18, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 15 ’25 when LEPORE PATRICK G bought 15,000 shares for $2.92 per share. The transaction valued at 43,800 led to the insider holds 51,472 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VYNE now has a Market Capitalization of 26997138 and an Enterprise Value of -23211874. For the stock, the TTM Price-to-Sale (P/S) ratio is 44.99 while its Price-to-Book (P/B) ratio in mrq is 0.59. Its current Enterprise Value per Revenue stands at -38.367.
Stock Price History:
The Beta on a monthly basis for VYNE is 1.64, which has changed by -0.177665 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, VYNE has reached a high of $4.30, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is 31.33%, while the 200-Day Moving Average is calculated to be -23.30%.
Shares Statistics:
VYNE traded an average of 388.77K shares per day over the past three months and 1520120 shares per day over the past ten days. A total of 15.96M shares are outstanding, with a floating share count of 13.61M. Insiders hold about 18.32% of the company’s shares, while institutions hold 36.72% stake in the company. Shares short for VYNE as of 1749772800 were 344165 with a Short Ratio of 0.89, compared to 1747267200 on 227933. Therefore, it implies a Short% of Shares Outstanding of 344165 and a Short% of Float of 2.09.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 2 analysts. It ranges from a high estimate of $200k to a low estimate of $100k. As of the current estimate, VYNE Therapeutics Inc’s year-ago sales were $198kFor the next quarter, 2 analysts are estimating revenue of $175k. There is a high estimate of $200k for the next quarter, whereas the lowest estimate is $150k.
A total of 2 analysts have provided revenue estimates for VYNE’s current fiscal year. The highest revenue estimate was $800k, while the lowest revenue estimate was $600k, resulting in an average revenue estimate of $700k. In the same quarter a year ago, actual revenue was $501k
